BLUE: bluebird bio Inc. Price-to-Revenue Ratio
bluebird bio, Inc. (BLUE) leads in blood gene therapy, ensuring high margins and stable cash flow. The price-to-sales ratio demonstrates valuation dynamics, where 0.50 reflects the latest metric value. Growth depends on Lyfgenia sales and insurance coverage, while the strategy shifts toward the industrial scaling of approved vectors and the implementation of commercial protocols.
Analytical breakdowns for bluebirdbio.com (BLUE)
- share price and consensus valuation forecast:
- market capitalization information:
- issuer book value statistics:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio bluebird bio, Inc.|BLUE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient bluebirdbio.com|BLUE - Company Debts|Debt to Book Value Ratio bluebird bio, Inc|BLUE - Company Long-Term Debts|Company Current Liabilities bluebird bio|Interim Coverage Ratio bluebirdbio.com
- net income and valuation ratios data:
BLUE - Net Profit|Expected Profit bluebird bio, Inc.|BLUE - Price to Earnings Ratio|Future Price to Earnings bluebird bio, Inc.|BLUE - Price/Earnings to Growth Multiple|EV/EBITDA Multiple bluebird bio, Inc|BLUE - Operating profit EBITDA|Net earnings per one share for the last twelve months bluebird bio|BLUE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months bluebirdbio.com|BLUE - Earnings per share growth in current year|Projected earnings per share growth rate for next year bluebird bio, Inc.
- total revenue and sales volume data:
Fundamental company analysis:bluebird bio (BLUE)
To select assets with a high margin of safety, analyzing the price-to-sales ratio is critical, as it allows for an assessment of business overvaluation relative to generated cash flow. This price-to-sales multiple reflects the monetization efficiency of bluebird bio, Inc. (BLUE) gene therapies, helping investors correlate the company's valuation with revenues from rare disease treatments and partnership payments.
Competing companies
TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|OCGN - P/S Multiple|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Therapeutics, Inc.|RCKT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Revenue Ratio|SLN - Price-to-Revenue Ratio|Price-to-Revenue Multiple ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Market Cap to Revenue|Sangamo Therapeutics Inc. (SGMO) - P/S Multiple|Price-to-Revenue Ratio Nautilus Bio|Price to Sales Metagenomi Therapeutics MGX|Price-to-Revenue Ratio Precision BioSciences (DTIL)|GBIO - Price to Sales|P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Market Cap to Revenue|IMNN - Price-to-Revenue Ratio|Price to Sales Phio Pharmaceuticals Corp|MBIO: P/S Multiple|TransCode (RNAZ) - P/S Multiple|BNGO (Bionano) - P/S Multiple|Price to Sales Applied DNA Sciences, Inc. APDN|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio
